Transforming Growth Factor beta1, Recombinant, Human, Ala279-Ser390 (TGF beta 1, TGFb1, Camurati Engelmann Disease, CED, Diaphyseal Dysplasia 1 Progressive, DPD1, TGFb1, Differentiation Inhibiting Factor, Cartilage-inducing Factor)

Transforming Growth Factor beta1 (TGFb1) activities include proliferation, angiogenesis and promotion or inhibition of many immune events. TGFb1 is produced by a number of cell types including regulatory T cells, fibroblasts, epithelial cells, and endothelial cells (3). TGFb1 binds to TBRII homodimer, which then complexes with TBRI homodimer. The oligomeric receptor complex phosphorylates subsets of the SMAD proteins that then act to induce and repress a number of target genes. TGFb1 binding can also activate the Erk2, p38, and JNK pathways via TAK1. TGFb1 appears to promote late stage progression and metastasis in some cancers.\n\nRecombinant human TGFb1 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,794. DTT-reduced protein migrates as a 13kD polypeptide and the non-reduced cystine-linked homodimer migrates as a 25kD protein. The expected amino-terminal ALDTN of recombinant human TGFb1 was verified by amino acid sequencing.\n\nBioactivity:\nDetermined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 is between 0.04-0.20ng/ml.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile 20mM citrate, pH 3. Use immediately. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

T8250-13B

Size

10ug

Applications

WB

Reactivities

Hum

Form

Supplied as a lyophilized powder from 20mM citrate, pH 3.0, 100mM sodium chloride. Reconstitute with sterile 20mM citrate, pH 3 to (same/more than)50ug/ml. May add protein to solution to minimize absorption of human TGFb1 to surfaces. Solubilize for 30 minutes at RT with occasional gentle vortexing.

Purity

(same/more than)98% by SDS-PAGE of 6ug reduced (+) and non-reduced (-) recombinant human TGFb1. <1% migrates as monomer human TGFb1 under non-reduced (-) conditions. Endotoxin: (same/less than)0.01ng/ug

References

1. Siegel, P.M. and Massague, J. (2003) Nat Rev Cancer 3, 807-21. 2. Bierie, B. and Moses, H.L. (2006) Nat Rev Cancer 6, 506-20. 3. Tian, M. and Schiemann, W.P. (2009) Future Oncol 5, 259-71, 4. Moustakas, A. and Heldin, C.H. (2009) Development 136, 3699-714..